Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.
MLN8054 is an ATP-competitive inhibitor of Aurora A kinase (IC50 = 4 nM).1 It is selective for Aurora A over Aurora B, PKC, CaMKII, Cdk2E, CK2, LCK, PKA, Chk1, Chk2, Cdk1, and Plk1 (IC50s = 0.172-100 µM). MLN8054 induces cell cycle arrest at the G2/M phase and the formation of abnormal mitotic spindles in HCT116 colorectal and PC3 prostate cancer cells. It inhibits the growth of HCT116, SW480, DLD-1, MCF-7, MDA-MB-231, Calu-6, H460, SKOV3, and PC3 cancer cells (IC50s = 0.11-1.43 µM). MLN8054 (30 mg/kg) reduces tumor volume in HCT116 and PC3 mouse xenograft models.
WARNING This product is not for human or veterinary use.
1. Antitumor activity of MLN8054, an orally active small-